Treatment by GCPII inhibitors has been effective in animalmodels of ischemic brain injury,11−13 traumatic brain injury,14 amyotrophic lateral sclerosis,15 inflammatory/neuropathic pain,16−19 and schizophrenia.20,21. The gene discussed is FOLH1; the disease is brain injury.